Editas Medicine (EDIT) Misses Q1 EPS by 13c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. APTX:CN
3. EROC
4. FRBT
5. SPGI
6. SEER
7. SNDK
8. TSLA
9. ONDS
10. SEI

Go back to Editas Medicine (EDIT) Misses Q1 EPS by 13c, Revenues Beat

UPDATE: RBC Capital Starts Editas Medicine (EDIT) at Sector Perform

May 3, 2021 4:12 PM EDT

(Updated - May 3, 2021 4:20 PM EDT)

RBC Capital analyst Luca Issi initiates coverage on Editas Medicine (NASDAQ: EDIT) with a Sector Perform rating and a price target of $40.00.

The analyst comments "EDIT has pioneered the field of gene editing... More